Optimer submits fidaxomicin MAA

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) submitted an MAA in Europe for fidaxomicin to treat Clostridium difficile infection. Optimer plans to submit an NDA in the U.S. this year. Fidaxomicin is a ...